Ultimovacs ASA: Annual Report 2023
21 mars 2024 02h00 HE
|
Ultimovacs ASA
Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs...
Ultimovacs ASA: Mandatory notification of trades by primary insider
09 mars 2024 05h00 HE
|
Ultimovacs ASA
Oslo, 9 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, sold on 8 March 2024, 400,000 shares in the company at an...
Ultimovacs ASA: Mandatory notification of trades by primary insider
08 mars 2024 17h00 HE
|
Ultimovacs ASA
Oslo, 8 March 2024: CGS Holding AS, a closely related party of Leiv Askvig, a board member and primary insider in Ultimovacs ASA, has today sold 140,000 shares in the company at an average price of...
Ultimovacs ASA: Mandatory notification of trade by primary insiders
07 mars 2024 17h00 HE
|
Ultimovacs ASA
Oslo, 7 March 2024: Langøya Invest AS, a closely related party of Ketil Fjerdingen, a board member and primary insider in Ultimovacs ASA, has today sold 596,006 shares in the company at an average...
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma
07 mars 2024 01h00 HE
|
Ultimovacs ASA
With the 18-month minimum follow-up of the patients in the INITIUM trial, the trial did not meet the primary endpoint of prolonging progression-free survival (PFS). Median PFS was not reached in...
Ultimovacs announces publication of results from NIPU Phase II trial with UV1 vaccination in mesothelioma in European Journal of Cancer
02 mars 2024 12h41 HE
|
Ultimovacs ASA
NON-REGULATORY PRESS RELEASE The NIPU trial is investigating the effect of adding UV1 vaccine to immunotherapy as second-line treatment of pleural mesothelioma. The results were initially...
Ultimovacs Receives EMA Orphan Drug Designation for UV1 Cancer Vaccine for the Treatment of Mesothelioma
19 févr. 2024 01h00 HE
|
Ultimovacs ASA
The Orphan Drug Designation (ODD) from the European Medicines Agency (EMA) was granted based on results from the randomized Phase II clinical trial NIPU, which showed improved overall survival...
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update
14 févr. 2024 01h00 HE
|
Ultimovacs ASA
Readout of topline result expected in March 2024 from UV1 randomized Phase II trial INITIUM in Ultimovacs’ lead indication, advanced malignant melanomaTopline result will report primary endpoint of...
Ultimovacs ASA: Invitation to fourth quarter 2023 results webcast presentation
08 févr. 2024 02h00 HE
|
Ultimovacs ASA
Oslo, February 8, 2023: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, invites to a webcast presentation of its fourth...
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma
05 févr. 2024 01h00 HE
|
Ultimovacs ASA
Fast Track designation is granted for UV1 in combination with ipilimumab and nivolumab for the treatment of patients with unresectable malignant pleural mesothelioma to improve overall...